Daily Cardiology Research Analysis
Analyzed 36 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stand out today: a prespecified MINT trial sub-study supports a liberal transfusion threshold in anemic myocardial infarction across age groups; a randomized trial shows a simple pigtail-assisted tracking technique reduces radial access complications in PCI; and a large MESA cohort analysis details sex-specific phenotypes and outcomes within the Cardiovascular-Kidney-Metabolic syndrome framework, informing tailored prevention.
Research Themes
- Transfusion strategy in myocardial infarction
- Access-site safety and technique optimization in PCI
- Sex-specific risk stratification in CKM syndrome
Selected Articles
1. Effect of Age on Restrictive and Liberal Transfusion Outcomes in Patients with Anemia and Myocardial Infarction.
In a prespecified sub-study of the 3,504-patient MINT RCT, there was no significant interaction between age and transfusion strategy across multiple outcomes at 30 and 180 days. A liberal transfusion threshold (10 g/dL) appears safe and potentially preferable to a restrictive threshold (8 g/dL) for anemic MI patients regardless of age.
Impact: Clarifies age does not modify the effect of transfusion strategy in anemic MI, supporting consistent practice across age groups. Reinforces potential preference for a liberal threshold in a high-stakes clinical scenario.
Clinical Implications: For anemic MI patients, clinicians can consider a liberal transfusion threshold irrespective of age, aligning with MINT’s overall findings, while individual bleeding/ischemia risks should still guide decisions.
Key Findings
- No significant age-by-strategy interaction for death or MI, HF, revascularization, cardiac death, PE/DVT, or bacteremia/pneumonia-related death at 30 and 180 days.
- Liberal transfusion threshold (Hb 10 g/dL) appears safe and potentially preferable vs restrictive (8 g/dL) in anemic MI irrespective of age.
- Parent MINT RCT randomized 3,504 patients and suggested advantages of liberal transfusion for death or MI.
Methodological Strengths
- Prespecified subgroup within a large, multicenter RCT (MINT) with registered protocol (NCT02981407).
- Multiple clinically relevant endpoints assessed at two time horizons (30 and 180 days).
Limitations
- Subgroup analysis; the study may be underpowered to detect modest age interactions.
- Generalizability may vary across care settings and transfusion practices.
Future Directions: Individual patient-level meta-analyses across transfusion trials and pragmatic implementation studies could validate uniform liberal thresholds across age and comorbidity strata.
For patients with anemia and myocardial infarction, the randomized, 3504-patient MINT trial found that a liberal transfusion threshold (10 g/dL) may be preferable to a restrictive threshold (8 g/dL) in terms of death or myocardial infarction. The relative effects of liberal versus restrictive transfusion in younger and older patients are unknown. The present prespecified MINT sub-study found no significant interaction between age and transfusion strategy for death or myocardial infarction, heart failure, revascularization procedures, cardiac death, pulmonary embolism or deep vein thrombosis, and bacteremia or pneumonia and death at 30 and 180 days. A liberal transfusion approach appears to be safe and may be the preferred transfusion strategy in anemic patients with myocardial infarction, regardless of age. MINT Trial, ClinicalTrials.gov Number NCT02981407, https://www.minttrial.org/.
2. Pigtail assisted tracking of guide catheter during transradial coronary angioplasty on forearm complications: prospective randomized trial.
In a 260-patient randomized trial of transradial PCI, pigtail-assisted tracking significantly reduced the composite of radial spasm, angiographic injury, forearm hematoma, and radial artery occlusion at 48 hours versus standard navigation. Non-use of PAT and low body weight independently predicted forearm complications.
Impact: Demonstrates a simple, low-cost technique that meaningfully improves safety of transradial PCI, a widely used access route.
Clinical Implications: Adopting PAT during transradial PCI can reduce early radial access complications, potentially preserving radial patency for future procedures and improving patient comfort.
Key Findings
- Primary composite outcome reduced with PAT: 11.5% vs 25.4% (p=0.004).
- Individual complications were lower with PAT: spasm 9.2% vs 21.5% (p=0.006); angiographic injury 3.1% vs 9.2% (p=0.04); hematoma 4.6% vs 13.1% (p=0.01); RAO 3.1% vs 10.0% (p=0.02).
- Non-use of PAT and low body weight independently predicted forearm complications.
Methodological Strengths
- Prospective randomized design with prespecified composite and individual safety endpoints.
- Objective assessment of radial artery patency by vascular Doppler at 48 hours.
Limitations
- Single-center study with short (48-hour) follow-up; blinding not reported.
- Generalizability to complex anatomies and diverse operator experience requires confirmation.
Future Directions: Multicenter trials with longer follow-up should assess durability of benefits, impact on long-term radial patency, and outcomes in high-risk subgroups.
OBJECTIVES: During transradial percutaneous intervention (PCI), sharp edge of guide catheter tip may produce "razor blade effect" leading to radial vascular injury. Pigtail assisted tracking (PAT) technique has been described to overcome it, but has not been systematically evaluated. We prospectively evaluated the safety and efficacy of PAT technique in transradial PCI. METHODS: Consecutive patients undergoing transradial-PCI were randomized into two groups (Group 1: transradial navigation using PAT technique, Group 2: transradial navigation without PAT technique). Patients were observed for forearm complications and radial artery patency was determined by vascular Doppler at 48 h. Primary end point was the composite incidence of radial artery spasm, angiographic radial artery injury, forearm hematoma and radial artery occlusion (RAO). Secondary end points were incidence of each of these individual variables. Predictors of forearm complications were determined by multivariate analysis. RESULT: Total 260 patients were finally included (130 patients in each group). Baseline and procedural characteristics were comparable in both groups. Majority [158 (60.8%) patients] had acute coronary syndrome. Primary outcome was significantly reduced by the PAT technique [15 (11.5%) vs. 33 (25.4%) patients; p = 0.004]. Individual outcomes were also significantly less in Group 1 [radial artery spasm 12 (9.2%) vs. 28 (21.5%), p = 0.006; angiographic radial artery injury 4 (3.1%) vs. 12 (9.2%), p = 0.04; forearm hematoma 6 (4.6%) vs. 17 (13.1%), p = 0.01; RAO 4 (3.1%) vs. 13 (10.0%), p = 0.02]. PCI without PAT technique and low body weight emerged as independent predictor for forearm complications. CONCLUSION: PAT technique is safe and significantly reduces the forearm complications.
3. Sex differences in cardiovascular-kidney-metabolic syndrome and new onset cardiovascular outcomes.
In 6,563 MESA participants free of CVD, men had higher CKM Stage 3 prevalence and a Stage 3 phenotype dominated by subclinical atherosclerosis (CAC≥100), while women exhibited a subclinical HF phenotype. Over 13.7 years, men had substantially higher CHD incidence (IR 20.9 vs 8.9), with SHRs of 2.28 for CHD and 1.66 for HF compared with women.
Impact: Provides actionable, sex-specific characterization of CKM stages and outcomes, enabling targeted prevention strategies and earlier detection of divergent phenotypes.
Clinical Implications: In CKM Stage 3, prioritize atherosclerosis detection and CHD prevention in men (e.g., CAC-guided strategies) and vigilance for subclinical HF in women (biomarker-driven surveillance), enabling sex-tailored risk management.
Key Findings
- Men had higher CKM Stage 3 prevalence (42.4% vs 36.4% in women).
- Within CKM Stage 3, men predominantly had subclinical atherosclerotic CVD (CAC≥100: 70.5%), whereas women had a subclinical HF phenotype (elevated cardiac biomarkers: 70.1%).
- Over median 13.7 years, men had higher CHD incidence (IR 20.9 vs 8.9); SHRs for men vs women: CHD 2.28 (1.84–2.82), HF 1.66 (1.20–2.30), stroke 1.07 (0.80–1.43).
Methodological Strengths
- Large, multi-ethnic, community-based cohort with long median follow-up (13.7 years).
- Use of AHA CKM staging and Fine-Gray competing risk models for robust outcome estimation.
Limitations
- Observational design with potential residual confounding.
- Definitions of subclinical HF rely on biomarker thresholds; external validation across assays/settings needed.
Future Directions: Prospective interventional studies should test sex-specific, stage-based CKM care pathways (e.g., CAC-guided prevention in men, biomarker-guided HF prevention in women).
BACKGROUND: Cardiovascular-Kidney-Metabolic (CKM) syndrome integrates metabolic risk factors, chronic kidney disease (CKD), and cardiovascular dysfunction, and is closely linked to cardiovascular disease (CVD) risk. We aimed to evaluate sex-specific differences in prevalence, components, and outcomes of CKM syndrome to inform strategies for personalized cardiovascular prevention. METHOD: We included 6563 participants without established CVD from the Multi-Ethnic Study of Atherosclerosis (MESA). CKM stages were defined according to American Heart Association criteria. We assessed sex-specific prevalence, component distributions, and incidence of coronary heart disease (CHD), heart failure (HF), stroke, and mortality. Incidence rates (IR) per 1000 person-years and Fine-Gray subdistribution hazard ratios (SHR) were estimated. RESULTS: Among 3095 men and 3468 women (mean age: 62 ± 10 years), men had a higher CKM Stage 3 prevalence (42.4% vs. 36.4% in women). Within Stage 3, subclinical atherosclerotic CVD (coronary artery calcium [CAC] score ≥ 100 Agatston unit) predominated in men (70.5%), whereas subclinical HF (elevated cardiac biomarkers) was more frequent in women (70.1%). During a median follow-up of 13.7 years (IQR 9.0-15.5 years), CHD incidence was higher in men (IR: 20.9 vs. 8.9 in women), followed by HF (IR: 7.2 vs. 4.5) and stroke (IR: 6.7 vs. 6.3). Using women as the reference, SHRs (95% CI) for men were 2.28 (1.84, 2.82) for CHD, 1.66 (1.20, 2.30) for HF, and 1.07 (0.80, 1.43) for stroke. CONCLUSIONS: Men exhibited a higher prevalence of advanced CKM Stages and a substantially greater CHD burden, while women showed a higher subclinical HF phenotype within CKM Stage 3. These findings support sex-specific, stage-based CKM assessment as an actionable framework for early risk stratification and tailored cardiovascular prevention.